Literature DB >> 2634246

Plasma 3,4-dihydroxyphenylglycol as a tool to assess the role of neuronal uptake in the anaesthetized rabbit.

T Halbrügge1, R Wölfel, K H Graefe.   

Abstract

(1.) The purpose of this study was to investigate the role of neuronal uptake in the appearance in plasma of the primary noradrenaline metabolite 3,4-dihydroxyphenylglycol (DOPEG). To this end, steady-state changes in mixed central-venous plasma concentrations of noradrenaline and DOPEG produced by noradrenaline infusions or by changes in sympathetic tone were determined in anaesthetized rabbits either under control conditions or after treatment with desipramine (2 mg kg-1). The steady-state kinetics of infused DOPEG were also evaluated. (2.) Infused DOPEG (2.9 nmol kg-1 min-1 i.v. for 75 min) reached steady-state concentrations in plasma within less than 30 min, disappeared from plasma with a half-life of 2.3 min and showed a total-body plasma clearance of 84.0 ml kg-1 min-1. (3.) Constant-rate infusions of noradrenaline (1.2-5.9 nmol kg-1 min-1 i.v. for 75 min) produced increases in plasma noradrenaline and DOPEG concentrations which were linearly related to the rate of noradrenaline infusion. Thus, the plasma clearance of infused noradrenaline (75.8 ml kg-1 min-1) as well as the increase in plasma DOPEG expressed in % of that in plasma noradrenaline (9.4%) was virtually independent of the noradrenaline infusion rate. (4.) Desipramine reduced the plasma clearance of infused noradrenaline by 35.4% and the increment in plasma DOPEG relative to that in plasma noradrenaline by 75.3%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2634246     DOI: 10.1007/bf00169681

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  The distribution of 3H-(+/-)noradrenaline in rabbit aortic strips after inhibition of the noradrenaline-metabolizing enzymes.

Authors:  M Henseling; E Eckert; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

2.  Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans.

Authors:  D S Goldstein; G Eisenhofer; R Stull; C J Folio; H R Keiser; I J Kopin
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

Review 3.  Catecholamine metabolism: basic aspects and clinical significance.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1985-12       Impact factor: 25.468

Review 4.  Neuronal and extraneuronal uptake and metabolism of catecholamines.

Authors:  K H Graefe; M Henseling
Journal:  Gen Pharmacol       Date:  1983

5.  Evidence for a physiological role of presynaptic alpha-adrenoceptors: modulation of noradrenaline release in the pithed rabbit.

Authors:  H Majewski; L Hedler; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-12       Impact factor: 3.000

6.  Estimation of intrasynaptic norepinephrine concentrations at vascular neuroeffector junctions in vivo.

Authors:  I J Kopin; Z Zukowska-Grojec; M A Bayorh; D S Goldstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

7.  Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension.

Authors:  D S Goldstein; D Horwitz; H R Keiser; R J Polinsky; I J Kopin
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

8.  The noradrenaline rate in the anaesthetized rabbit: facilitation by adrenaline.

Authors:  H Majewski; L Hedler; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

9.  Effect of norepinephrine uptake blockers on norepinephrine kinetics.

Authors:  M Esler; G Jackman; P Leonard; H Skews; A Bobik; P Korner
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

10.  Assay of catecholamines and dihydroxyphenylethyleneglycol in human plasma and its application in orthostasis and mental stress.

Authors:  T Halbrügge; T Gerhardt; J Ludwig; E Heidbreder; K H Graefe
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

View more
  11 in total

1.  The heterogeneity of the neuronal distribution of exogenous noradrenaline in the rat vas deferens.

Authors:  E Schömig; C L Schönfeld; T Halbrügge; K H Graefe; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog.

Authors:  G Eisenhofer; J J Smolich; M D Esler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

3.  Effects of catechol-O-methyltransferase inhibition on the plasma clearance of noradrenaline and the formation of 3,4-dihydroxyphenylglycol in the rabbit.

Authors:  T Halbrügge; B Friedgen; J Ludwig; K H Graefe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

4.  Desipramine inhibits sympathetic nerve activity in the rabbit.

Authors:  B Sazbo; A Schultheiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

5.  Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats.

Authors:  G Eisenhofer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

6.  Inhibition of uptake 1 by (+)-oxaprotiline reveals a differential central regulation of noradrenaline and adrenaline release.

Authors:  B Szabo; T Auberle; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

7.  Parallel increases in noradrenaline reuptake and release into plasma during activation of the sympathetic nervous system in rabbits.

Authors:  G Eisenhofer; H S Cox; M D Esler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

Review 8.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

9.  Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.

Authors:  N H Holford; T W Guentert; J Dingemanse; L Banken
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

10.  Estimation of noradrenaline concentrations in the axoplasm of noradrenergic neurones in man.

Authors:  J Ludwig; T Halbrügge; M Gerlich; K H Graefe
Journal:  Clin Auton Res       Date:  1992-06       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.